Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-1763

To Learn More Call
201-510-0910

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
C34005

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MM 61

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Randomized, Open-Label Study of Com